DOCSLIB.ORG

Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table of Contents CONTENTS 1. The Normal Pituitary Gland ......................................................................................... 1 Gross Anatomy .......................................................................................................... 1 Vascular Supply ...................................................................................................... 4 Nerve Supply .......................................................................................................... 8 Embryology ................................................................................................................ 8 Microscopic and Functional Anatomy ...................................................................... 10 Hypothalamus and Neurohypophysis ................................................................... 10 Adenohypophysis ................................................................................................... 12 Adenohypophyseal Cells ........................................................................................ 17 Localization of Other Peptides in the Adenohypophysis ...................................... 34 2. Methods in Pituitary Pathology ................................................................................... 41 Gross Examination .................................................................................................... 41 The Autopsy Pituitary ............................................................................................. 41 The Surgical Specimen ............................................................................................ 42 Intraoperative Consultation ...................................................................................... 42 Histology and Immunohistochemistry ..................................................................... 43 Electron Microscopy .................................................................................................. 47 Tissue Culture ............................................................................................................ 47 Flow Cytometry ......................................................................................................... 49 Molecular Analysis ..................................................................................................... 49 A Practical Approach to the Diagnosis of a Pituitary Tumor .................................... 49 3. Pituitary Adenomas ...................................................................................................... 55 Epidemiology ............................................................................................................. 55 Classification Systems ................................................................................................ 58 Functional Classification ........................................................................................ 58 Anatomic or Radiologic Classification ................................................................... 58 Histologic Classification ......................................................................................... 61 Immunohistochemical Classification .................................................................... 61 Ultrastructural Classification .................................................................................. 62 Clinicopathologic Classification ............................................................................ 63 Adenomas Causing Adrenocorticotropic Excess ....................................................... 63 Clinical Features ..................................................................................................... 63 Biochemical Findings ............................................................................................. 65 Radiologic Findings ................................................................................................ 66 Gross Findings ........................................................................................................ 66 Microscopic Findings .............................................................................................. 67 ix Tumors of the Pituitary Gland Differential Diagnosis ............................................................................................. 74 Treatment and Prognosis ........................................................................................ 75 Adenomas Causing Growth Hormone Excess ........................................................... 76 Clinical Features ..................................................................................................... 76 Biochemical Findings ............................................................................................. 77 Radiologic Findings ................................................................................................ 78 Gross Findings ........................................................................................................ 78 Microscopic Findings .............................................................................................. 78 Differential Diagnosis ............................................................................................. 90 Treatment and Prognosis ........................................................................................ 91 Adenomas Causing Prolactin Excess ......................................................................... 93 Clinical Features ..................................................................................................... 93 Biochemical Findings ............................................................................................. 93 Radiologic Findings ................................................................................................ 94 Gross Findings ........................................................................................................ 95 Microscopic Findings .............................................................................................. 95 Differential Diagnosis ............................................................................................. 105 Treatment and Prognosis ........................................................................................ 106 Adenomas Causing Thyrotropin Excess .................................................................... 108 Clinical Features ..................................................................................................... 108 Biochemical Findings ............................................................................................. 109 Radiologic Findings ................................................................................................ 109 Gross Findings ........................................................................................................ 109 Microscopic Findings .............................................................................................. 109 Differential Diagnosis ............................................................................................. 113 Treatment and Prognosis ........................................................................................ 113 Adenomas Causing Gonadotropin Excess ................................................................. 113 Clinical Features ..................................................................................................... 113 Biochemical Findings ............................................................................................. 114 Radiologic Findings ................................................................................................ 114 Gross Findings ........................................................................................................ 114 Microscopic Findings .............................................................................................. 114 Differential Diagnosis ............................................................................................. 117 Treatment and Prognosis ........................................................................................ 118 Clinically Nonfunctioning Adenomas ...................................................................... 120 Clinical Features ..................................................................................................... 120 Biochemical Findings ............................................................................................. 120 Radiologic Findings ................................................................................................ 120 Microscopic Findings .............................................................................................. 120 x Contents Differential Diagnosis ............................................................................................. 135 Treatment and Prognosis ........................................................................................ 136 Plurihormonal and Double Adenomas ..................................................................... 136 Clinical Features ..................................................................................................... 136 Biochemical Findings ............................................................................................. 137 Radiologic Findings ...............................................................................................
Load more

Recommended publications
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult With
    Khalayleh et al. Int Arch Endocrinol Clin Res 2017, 3:008 Volume 3 | Issue 1 International Archives of Endocrinology Clinical Research Case Report : Open Access Adrenal Neuroblastoma Mimicking Pheochromocytoma in an Adult with Neurofibromatosis Type 1 Harbi Khalayleh1, Hilla Knobler2, Vitaly Medvedovsky2, Edit Feldberg3, Judith Diment3, Lena Pinkas4, Guennadi Kouniavsky1 and Taiba Zornitzki2* 1Department of Surgery, Hebrew University Medical School of Jerusalem, Israel 2Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Israel 3Pathology Institute, Kaplan Medical Center, Israel 4Nuclear Medicine Institute, Kaplan Medical Center, Israel *Corresponding author: Taiba Zornitzki, MD, Endocrinology, Diabetes and Metabolism Institute, Kaplan Medical Center, Hebrew University Medical School of Jerusalem, Bilu 1, 76100 Rehovot, Israel, Tel: +972-894- 41315, Fax: +972-8 944-1912, E-mail: [email protected] Context 2. This is the first reported case of an adrenal neuroblastoma occurring in an adult patient with NF1 presenting as a large Neurofibromatosis type 1 (NF1) is a genetic disorder asso- adrenal mass with increased catecholamine levels mimicking ciated with an increased risk of malignant disorders. Adrenal a pheochromocytoma. neuroblastoma is considered an extremely rare tumor in adults and was not previously described in association with NF1. 3. This case demonstrates the clinical overlap between pheo- Case description: A 42-year-old normotensive woman with chromocytoma and neuroblastoma. typical signs of NF1 underwent evaluation for abdominal pain, Keywords and a large 14 × 10 × 16 cm left adrenal mass displacing the Adrenal neuroblastoma, Neurofibromatosis type 1, Pheo- spleen, pancreas and colon was found. An initial diagnosis of chromocytoma, Neural crest-derived tumors pheochromocytoma was done based on the known strong association between pheochromocytoma, NF1 and increased catecholamine levels.
    [Show full text]
  • Cerebellar Neuroblastoma in 2.5 Years Old Child
    Case Report Cerebellar Neuroblastoma in 2.5 Years Old Child Mohammad Pedram1, Majid Vafaie1, Kiavash Fekri1, Sabahat Haghi1, Iran Rashidi2, Chia Pirooti3 Abstract 1. Thalassemia and Neuroblastoma is the third most common malignancy of childhood, after leukemia Hemoglobinopathy Research Center, Ahvaz Jondishapur University of and brain tumors. Only 2% of all neuroblastoma occur in the brain. Primary Medical Sciences, Ahvaz, Iran cerebellar neuroblastoma is an specific subset of Primitive Neuroectodermal 2. Dept. of Pathology, Shafa Tumors (PNET). Meduloblastoma is a relatively common and well-established Hospital , Ahvaz Jondishapur entity, consisting of primitive and multipotential cells that may exhibit some University of Medical Sciences, evidence of neuroblastic or gliad differentiation. But cerebellar neuroblastoma Ahvaz, Iran with ultrastractural evidence of significant neuroblastic differentiation is 3. Dept. of Neurosurgery, Golestan extremely rare. We report a rare case of neuroblastoma in the cerebellum. A Hospital, Ahvaz Jondishapur 2.5-year-old Iranian boy presented with vomiting and nausea in the morning and University of Medical Sciences, ataxia. CT scan showed a tumor mass in the cerebellum and the report of Ahvaz, Iran radiologist was medulloblastoma. Light microscopic assay showed a small cell Corresponding Author: neoplasm with lobules of densely packed cells (lobulated pattern) and better Mohammad Pedram, MD; differentiated cells. Neuron-Specific Enolase was positive. Pathologic diagnosis Professor of Pediatrics Hematology- confirmed the existence of cerebellar neuroblastoma. Chemotherapy followed Oncology surgical removal. No relapse occurred 12 months after surgery. Tel: (+98) 611 374 32 85 Email: Keywords: Neuroblastoma; Cerebellum; Chemotherapy [email protected] Please cite this article as: Pedram M, Vafaie M, Fekri K, Haghi S, Rashidi I, Pirooti Ch.
    [Show full text]
  • Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: an Overview Comparing Pediatric and Adult Populations
    cancers Review Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations 1, 2, 2 3 Aline Rangel-Pozzo y, Luiza Sisdelli y, Maria Isabel V. Cordioli , Fernanda Vaisman , Paola Caria 4,*, Sabine Mai 1,* and Janete M. Cerutti 2 1 Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada; [email protected] 2 Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo/EPM, São Paulo, SP 04039-032, Brazil; [email protected] (L.S.); [email protected] (M.I.V.C.); [email protected] (J.M.C.) 3 Instituto Nacional do Câncer, Rio de Janeiro, RJ 22451-000, Brazil; [email protected] 4 Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy * Correspondence: [email protected] (P.C.); [email protected] (S.M.); Tel.: +1-204-787-2135 (S.M.) These authors contributed equally to this paper. y Received: 29 September 2020; Accepted: 26 October 2020; Published: 27 October 2020 Simple Summary: Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence clinical and biological behavior in both children and adults. In this review, we focus on the comparison between pediatric and adult PTC, highlighting genetic alterations, telomere-related genomic instability and changes in nuclear organization as novel biomarkers for thyroid cancers. Abstract: Thyroid cancer is a rare malignancy in the pediatric population that is highly associated with disease aggressiveness and advanced disease stages when compared to adult population.
    [Show full text]
  • 493.Full.Pdf
    THE MERICAN JOURNAL OF CANCER A Continuation of The Journal of Cancer Research VOLUMEXXXVI I DECEMBER,1939 NUMBER4 GLIOMAS IN ANIMALS A REPORTOF Two ASTROCYTOMASIN THE COMMONFOWL ERWIN JUNGHERR, D.M.V., AND ABNER WOLF, M.D. (From the Department of Animal Diseases, Storrs Agricultural Experiment Station; the Department of Neuropathology, Columbia University; the Neurological Institute of New York) In one of the first modern studies of comparative tumor pathology, Bland- Sutton (4) stated that ‘‘ no tumors are peculiar to man.” While this view was supported in general by subsequent observations, the infreqhent reports of gliomas and other tumors of the central nervous system in animals other than man seemed to be significant. This low incidence, however, is probably more apparent than real. In a recent dissertation on the subject, Grun (20) points out that post-mortem examination of the brain in animals is performed com- paratively infrequently and that possible carriers of tumors of the central nerv- ous system are often disposed of by slaughter without adequate study. Enhanced interest in the study of brain tumors in man has been reflected in the increased number of reports of cerebral neoplasms in animals, espe- cially during the past decade, but many of these cases have been so inade- quately described that even an approximate classification is difficult. There is thus a definite need for wider information on the comparative pathology of tumors of the nervous system. The present communication aims to contribute to the subject by a brief critical review of the literature on gliomas in the lower animals, and by the reports of two additional cases in the common fowl.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Lesions of the Sellar Region Which May Resemble Macroadenomas Lesiones De La Región Selar Que Pueden Parecerse a Macroadenomas
    www.analesderadiologiamexico.com PERMANYER Anales de Radiología México 2016;15(4):251-259 www.permanyer.com ORIGINAL ARTICLE Lesions of the sellar region which may resemble macroadenomas Lesiones de la región selar que pueden parecerse a macroadenomas Stelios Cedi-Zamudio1, M. Gray-Lugo1, A.E. Vega-Gutiérrez2, V.H. Ramos-Pacheco3, L. Manola-Aguilar4 and G.M. Guerrero-Avendaño5 1Médico Residente del Servicio de Radiología e Imagen; 2Medico Radiólogo especialista en Resonancia Magnética; 3Médico Residente de Curso de Alta Especialidad en el servicio de Resonancia Magnética; 4Médico Residente del Servicio de Neuropatología; 5Medico Radiólogo Intervencionista. Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México ABSTRACT Correspondence to: Stelios Cedi-Zamudio Médico Residente del Servicio de Radiología e Imagen Hospital General de México Dr. Eduardo Liceaga Ciudad de México, México Received in original form: 22-07-2016 E-mail: [email protected] Accepted in final form: 17-09-2016 1665-2118/©2018 Sociedad Mexicana de Radiologia e Imagen, AC. Publicado por Permanyer México SA de CV. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/). Anales de Radiología México. 2016;15 INTRODUCTION are headache, endocrinological disturbances that can be associated to hypopituitarism, hy- The study of the sellar region has had import- perprolactinemia, hypersecretion of growth ant changes throughout time with the evolu- hormone, pituitary apoplexy, and III, IV, and tion of imaging methods that have growingly VI cranial nerve disorders with optic neurop- improved the resolution of images and have athy leading to diplopia with cavernous sinus displaced diagnostic studies used in the 70s syndrome.1 and 80s last century, such as angiography or pneumoencephalography as the first choice The use of MRI as a standard method pro- methods for diagnosis; computed tomogra- vides more information about disorders in phy and magnetic resonance imaging (MRI) the sellar region.
    [Show full text]
  • Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies
    International Journal of Molecular Sciences Review Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies 1, 2, 2 2, Kinga B. Stopa y , Agnieszka A. Kusiak y, Mateusz D. Szopa , Pawel E. Ferdek * and Monika A. Jakubowska 1,* 1 Malopolska Centre of Biotechnology, Jagiellonian University, ul. Gronostajowa 7A, 30-387 Krakow, Poland; [email protected] 2 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, ul. Gronostajowa 7, 30-387 Krakow, Poland; [email protected] (A.A.K.); [email protected] (M.D.S.) * Correspondence: [email protected] (P.E.F.); [email protected] (M.A.J.) These authors contributed equally to this work. y Received: 9 April 2020; Accepted: 29 April 2020; Published: 1 May 2020 Abstract: Pancreatic ductal adenocarcinoma (PDAC) causes annually well over 400,000 deaths world-wide and remains one of the major unresolved health problems. This exocrine pancreatic cancer originates from the mutated epithelial cells: acinar and ductal cells. However, the epithelia-derived cancer component forms only a relatively small fraction of the tumor mass. The majority of the tumor consists of acellular fibrous stroma and diverse populations of the non-neoplastic cancer-associated cells. Importantly, the tumor microenvironment is maintained by dynamic cell-cell and cell-matrix interactions. In this article, we aim to review the most common drivers of PDAC. Then we summarize the current knowledge on PDAC microenvironment, particularly in relation to pancreatic cancer therapy. The focus is placed on the acellular stroma as well as cell populations that inhabit the matrix.
    [Show full text]
  • What Can the Neuroradiologist Really Say?
    The New World Health Organization Classification of Central Nervous System Tumors: REVIEW ARTICLE What Can the Neuroradiologist Really Say? A.G. Osborn SUMMARY: The WHO Classification of Tumors of the Central Nervous System has become the K.L. Salzman worldwide standard for classifying and grading brain neoplasms. The most recent edition (WHO 2007) introduced a number of significant changes that include both additions and redefinitions or clarifica- M.M. Thurnher tions of existing entities. Eight new neoplasms and 4 new variants were introduced. This article J.H. Rees reviews these entities, summarizing both their histology and imaging appearance. Now with more than M. Castillo 3 years of clinical experience following publication of the newest revision, we also ask, “What can the neuroradiologist really say?” Are there imaging findings that could suggest the preoperative diagnosis of a new tumor entity or variant? ABBREVIATIONS: aCPP ϭ atypical choriod plexus papilloma; CNS ϭ central nervous system; CPP ϭ choriod plexus papilloma; CPCa ϭ choriod plexus carcinoma; DNET ϭ dysembryoplastic neuroep- ithelial tumor; EVNCT ϭ extraventricular neurocytoma; MB ϭ medulloblastoma; MBEN ϭ medul- loblastoma with extensive nodularity; PA ϭ pilocytic astrocytoma; PGNT ϭ papillary glioneuronal tumor; PMA ϭ pilomyxoid astrocytoma; PPTID ϭ pineal parenchymal tumor of intermediate differentiation; PTPRϭ papillary tumor of the pineal region; RGNT ϭ rosette-forming glioneuronal tumor; SCO ϭ spindle cell oncocytoma; T1Cϩϭpost-contrast T1-weighted; T1WI ϭ T1-weighted imaging; T2WI ϭ T2-weighted imaging; WHO ϭ World Health Organization he WHO Classification of Tumors of the Central Nervous mors”) as chordoid glioma and astroblastoma.4 Angiocentric TSystem, now in its fourth edition, is the universal standard gliomas are slowly growing solid hemispheric tumors of chil- 1,2 for classifying and grading brain neoplasms.
    [Show full text]
  • Risk Factors for Neuroblastoma
    cancer.org | 1.800.227.2345 Neuroblastoma Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that increases your chances of getting a disease such as cancer. Learn more about the risk factors for neuroblastoma. ● Risk Factors for Neuroblastoma ● What Causes Neuroblastoma? Prevention The risk of many adult cancers can be reduced with certain lifestyle changes , but at this time there are no known ways to prevent most cancers in children. The only known risk factors for neuroblastoma cannot be changed. There are no known lifestyle-related or environmental causes of neuroblastoma at this time. ● Can Neuroblastoma Be Prevented? Risk Factors for Neuroblastoma A risk factor is anything that increases the chances of getting a disease such as cancer. Different types of cancer have different risk factors. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Lifestyle-related risk factors such as body weight, physical activity, diet, and the use of tobacco and alcohol play a major role in many adult cancers. But these factors usually take many years to influence cancer risk, and they are not thought to play much of a role in childhood cancers, including neuroblastomas. No environmental factors (such as being exposed to chemicals or radiation during the mother’s pregnancy or in early childhood) are known to increase the chance of getting neuroblastoma. Age Neuroblastoma is most common in infants and very young children. It is very rare in people over the age of 10 years. Heredity Most neuroblastomas do not seem to run in families. But in about 1% to 2% of cases, children with neuroblastoma have a family history of it.
    [Show full text]
  • Pituicytoma with Significant Tumor Vascularity Mimicking Pituitary Macroadenoma
    Brain Tumor Res Treat 2017;5(2):110-115 / pISSN 2288-2405 / eISSN 2288-2413 CASE REPORT https://doi.org/10.14791/btrt.2017.5.2.110 Pituicytoma with Significant Tumor Vascularity Mimicking Pituitary Macroadenoma Hyuk Ki Shim1, Seung Heon Cha1, Won Ho Cho1, Sung-Hye Park2 1Department of Neurosurgery, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea 2Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea A 19-year-old man presented with bitemporal hemianopsia and was found to have a large sellar and Received July 23, 2017 suprasellar tumor, resembling a pituitary macroadenoma. Emergency transsphenoidal approach was Revised August 19, 2017 attempted because of rapid visual deterioration with headache. However, the approach was compli- Accepted August 21, 2017 cated and stopped by uncontrolled hemorrhage from the tumor. After conventional cerebral angiogra- Correspondence phy and recognition of an unusual pathology, transcranial approach was achieved to prevent permanent Seung Heon Cha visual loss. The final pathological diagnosis was pituicytoma with epithelioid features. Pituicytoma is a Department of Neurosurgery, rare low-grade tumor (WHO Grade I) of pituicytes involving the sellar and suprasellar region, and origi- Pusan National University nating from special glial cells of the neurohypophysis. Because of the high vascularity, the firm consis- School of Medicine, tency, and invasion to surrounding neurovascular structures, a pituicytoma should be included in the Pusan National University Hospital, differential diagnosis of a mass in the sellar and suprasellar area if the tumor shows high enhancement 179 Gudeok-ro, Seo-gu, Busan 49241, Korea with vascular components.
    [Show full text]